Tag Archives: Biotechnology and Pharmaceuticals

CETP Inhibitors: Blockbusters that Never Ran?

The news that Roche scrapped development on its CETP inhibitor dalcetrapib, a drug designed to raise HDL cholesterol in the blood, likely presages the shuttering of Lilly’s development program for its CETP inhibitor, evacetrapib, industry experts and analysts say.
Posted in Biotech, leadership, R&D, Technology | Also tagged , , , , , , | Leave a comment

Study: Future of Personalized Medicine

An increased focus on targeted medicine has become a staple for all facets of healthcare, from drug developers to consumers to pharma companies. Gerson Lehrman and Bloomberg jointly commissioned a survey that gauged the reactions and predictions of this trend from 52 leading US physicians. The survey covered a number of topics to assess which […]
Posted in R&D | Also tagged , , , , , , | 1 Comment

GSK Scores High in Market Access

GlaxoSmithKline ranked number one in a study of pharmaceutical companies offering access to medicines to emerging and developing nations, proving that the UK drug giant has a far stronger grasp on new markets than its US and Japanese counterparts. The study ranks 20 companies based on significant criteria including pricing, patents and intellectual properties, capacity […]
Posted in Emerging Markets, Strategy | Also tagged , , , , , , | Leave a comment

Takeda Launches New Plan, Cuts US Jobs

Image via Wikipedia The Japanese are taking a play from the US pharmaceutical industry’s rulebook and restructuring itself under the auspices of a fun catch phrase: “Transformation for a New Takeda.” The punch line, however, isn’t too funny. According to a two-year mid-range plan announced yesterday, Takeda will cut about 1,400 positions in the US […]
Posted in Strategy | Also tagged , , , , , , , | Leave a comment

InterMune Denied Approval for Lung Treatment

Image via Wikipedia Biotech firm InterMune took an ugly hit on Tuesday as news broke that its lung disease drug Esbriet (pirfenidone) will require additional clinical studies, and won’t be getting the seal of approval from FDA any time soon. The news caused InterMune’s stock to drop a staggering 78 percent, according to Reuters. Analysts […]
Posted in FDA, Strategy | Also tagged , , , , , | 1 Comment
  • Categories

  • Meta